Zealand Pharma A/S (ZLDPF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zealand Pharma A/S (ZLDPF) with AI Score 68/100 (Buy). Zealand Pharma A/S is a biotechnology company focused on developing peptide-based medicines for gastrointestinal and metabolic diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Zealand Pharma A/S (ZLDPF) Healthcare & Pipeline Overview
Zealand Pharma A/S, a Danish biotechnology firm, specializes in peptide-based therapeutics targeting gastrointestinal and metabolic disorders. With marketed products like Adlyxin and Lyxumia, and a pipeline featuring Dasiglucagon and glepaglutide, Zealand Pharma addresses unmet needs in specialty disease areas, collaborating with major pharmaceutical companies.
Investment Thesis
Zealand Pharma A/S presents a compelling investment case based on its focus on peptide-based therapeutics for gastrointestinal and metabolic diseases. The company's existing portfolio, including Adlyxin and Lyxumia, generates revenue, while its pipeline, featuring Dasiglucagon and glepaglutide, holds significant potential. The Phase III clinical trials for Dasiglucagon in congenital hyperinsulinism and glepaglutide in short bowel syndrome could lead to significant market opportunities if approved. With a market capitalization of $2.89 billion and a profit margin of 70.0%, Zealand Pharma demonstrates financial strength. Potential risks include clinical trial failures and competition from other pharmaceutical companies. The company's collaborations with Sanofi, Boehringer Ingelheim, Alexion, and Beta Bionics further validate its technology and market position.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.89 billion indicates substantial investor confidence in Zealand Pharma's potential.
- Profit margin of 70.0% showcases the company's ability to generate significant earnings from its revenue streams.
- Gross margin of 99.8% reflects efficient cost management and strong pricing power.
- Beta of 0.42 suggests lower volatility compared to the overall market, potentially offering a more stable investment.
- The company's focus on peptide-based medicines targets high-growth therapeutic areas like diabetes and gastrointestinal disorders.
Competitors & Peers
Strengths
- Strong expertise in peptide-based drug development.
- Marketed products generating revenue.
- Promising pipeline with Phase III clinical trials.
- Strategic collaborations with major pharmaceutical companies.
Weaknesses
- Reliance on a limited number of products.
- High R&D expenses.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
Catalysts
- Upcoming: Phase III clinical trial results for Dasiglucagon in congenital hyperinsulinism.
- Upcoming: Phase III clinical trial results for glepaglutide in short bowel syndrome.
- Ongoing: Continued commercialization of Adlyxin and Lyxumia.
- Ongoing: Expansion of strategic collaborations with pharmaceutical companies.
- Ongoing: Development of the Dasiglucagon dual-hormone artificial pancreas.
Risks
- Potential: Clinical trial failures for Dasiglucagon and glepaglutide.
- Potential: Regulatory delays or rejections for new drug approvals.
- Ongoing: Competition from other pharmaceutical companies.
- Ongoing: Patent expirations on key products.
- Potential: Product liability claims.
Growth Opportunities
- Expansion of Dasiglucagon: Dasiglucagon holds significant growth potential in treating severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia. The market for hypoglycemia treatments is projected to reach $1.4 billion by 2028, driven by the increasing prevalence of diabetes and related complications. Successful completion of Phase III clinical trials and subsequent regulatory approvals could significantly boost Zealand Pharma's revenue.
- Glepaglutide for Short Bowel Syndrome: Glepaglutide, a long-acting GLP-2 analog, targets short bowel syndrome (SBS), a rare and debilitating condition. The SBS market is estimated at $2 billion, with limited treatment options available. Positive Phase III trial results and regulatory approval could establish glepaglutide as a key therapy in this niche market, providing substantial revenue growth for Zealand Pharma.
- Strategic Collaborations: Zealand Pharma's existing collaborations with Sanofi, Boehringer Ingelheim, Alexion, and Beta Bionics provide opportunities for further drug development and commercialization. These partnerships can leverage Zealand Pharma's peptide technology and expertise, potentially leading to new products and revenue streams. Expanding these collaborations or forming new ones could accelerate the company's growth trajectory.
- Geographic Expansion: While Zealand Pharma is headquartered in Denmark, expanding its geographic reach could unlock new market opportunities. Targeting regions with high prevalence of diabetes and gastrointestinal disorders, such as North America and Asia, could drive revenue growth. Establishing a commercial presence in these regions or partnering with local distributors could facilitate this expansion.
- Pipeline Development: Investing in research and development to expand its pipeline of peptide-based medicines is crucial for Zealand Pharma's long-term growth. Focusing on novel targets and therapeutic areas with unmet medical needs can lead to the discovery of innovative treatments. Successful development and commercialization of these new products can diversify the company's revenue streams and enhance its market position.
Opportunities
- Expansion into new therapeutic areas.
- Geographic expansion into underserved markets.
- Development of new peptide-based technologies.
- Acquisition of complementary businesses.
Threats
- Clinical trial failures.
- Patent expirations.
- Competition from biosimilars.
- Changes in regulatory landscape.
Competitive Advantages
- Proprietary Peptide Technology: Zealand Pharma's expertise in peptide-based drug discovery and development provides a competitive advantage.
- Patent Protection: Patents on its drugs and technologies protect its market exclusivity and pricing power.
- Strategic Collaborations: Partnerships with major pharmaceutical companies enhance its research and development capabilities and market reach.
- Specialized Focus: Focusing on niche therapeutic areas like congenital hyperinsulinism and short bowel syndrome allows it to establish a strong market position.
About ZLDPF
Zealand Pharma A/S, established in 1998 and headquartered in Copenhagen, Denmark, is a biotechnology company dedicated to the discovery, development, and commercialization of innovative peptide-based medicines. The company focuses primarily on addressing unmet medical needs within gastrointestinal and metabolic diseases, along with other specialized disease areas. Zealand Pharma's marketed products include lixisenatide, sold under the brand names Adlyxin and Lyxumia, used in the treatment of type 2 diabetes. Furthermore, the company markets Dasiglucagon, available in both single-use syringe and autoinjector formats, designed to treat severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia. They are also developing a Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline features Dasiglucagon, currently in Phase III clinical trials for congenital hyperinsulinism, and glepaglutide, a long-acting GLP-2 analog, also in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma has established collaboration agreements with prominent pharmaceutical companies such as Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc., enhancing its research and development capabilities and market reach.
What They Do
- Discovers and develops peptide-based medicines.
- Focuses on gastrointestinal and metabolic diseases.
- Commercializes treatments for diabetes and hypoglycemia.
- Develops a dual-hormone artificial pancreas for diabetes management.
- Conducts Phase III clinical trials for congenital hyperinsulinism and short bowel syndrome.
- Collaborates with pharmaceutical companies for research and development.
Business Model
- Develops and patents novel peptide-based drugs.
- Conducts clinical trials to demonstrate safety and efficacy.
- Obtains regulatory approvals for commercialization.
- Markets and sells its products directly or through partners.
- Generates revenue through product sales and licensing agreements.
Industry Context
Zealand Pharma operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The market for peptide-based therapeutics is expanding, driven by the increasing prevalence of metabolic and gastrointestinal disorders. Zealand Pharma competes with other biotechnology and pharmaceutical companies, including AKBLF, CAMRF, GNNSF, HKMPF, and HKMPY, in developing and commercializing innovative treatments. The company's focus on specialized disease areas and its collaboration agreements position it favorably within this competitive landscape.
Key Customers
- Patients with type 2 diabetes using Adlyxin and Lyxumia.
- Patients with severe hypoglycemia using Dasiglucagon.
- Patients with congenital hyperinsulinism.
- Patients with short bowel syndrome.
Financials
Chart & Info
Zealand Pharma A/S (ZLDPF) stock price: Price data unavailable
Latest News
-
Resolutions from Zealand Pharma's Annual General Meeting 2026
Yahoo! Finance: ZLDPF News · Mar 26, 2026
-
Assessing Zealand Pharma (CPSE:ZEAL) Valuation As New Cambridge Research Hub Expands AI Drug Discovery
Yahoo! Finance: ZLDPF News · Mar 25, 2026
-
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation
Yahoo! Finance: ZLDPF News · Mar 24, 2026
-
Zealand Pharma Announces Share Capital Increase
Yahoo! Finance: ZLDPF News · Mar 19, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZLDPF.
Price Targets
Wall Street price target analysis for ZLDPF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ZLDPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Resolutions from Zealand Pharma's Annual General Meeting 2026
Assessing Zealand Pharma (CPSE:ZEAL) Valuation As New Cambridge Research Hub Expands AI Drug Discovery
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation
Zealand Pharma Announces Share Capital Increase
Leadership: Adam Sinding Steensberg
CEO
Adam Sinding Steensberg serves as the CEO of Zealand Pharma A/S, leading a team of 385 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions, contributing to strategic decision-making and operational efficiency. Steensberg's expertise spans drug development, commercialization, and corporate management. His educational background includes advanced degrees in relevant scientific and business disciplines.
Track Record: Under Adam Sinding Steensberg's leadership, Zealand Pharma A/S has focused on advancing its pipeline of peptide-based medicines. Key achievements include the progression of Dasiglucagon and glepaglutide into Phase III clinical trials. He has also overseen the expansion of the company's strategic collaborations and the continued commercialization of existing products like Adlyxin and Lyxumia.
ZLDPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Zealand Pharma A/S (ZLDPF) may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB, or for listing on major exchanges such as the NYSE or NASDAQ. Companies on this tier may have limited information available to investors, and the regulatory oversight is less stringent compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the risk of investing in ZLDPF.
- Lower Liquidity: Reduced trading volume and wider bid-ask spreads can make it difficult to execute trades efficiently.
- Price Volatility: The stock may be subject to significant price swings due to lower trading volume and market speculation.
- Regulatory Uncertainty: The OTC Other tier has less regulatory oversight, increasing the risk of fraud or mismanagement.
- Information Scarcity: Limited information about the company's operations and financial performance makes it challenging to assess its true value.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Established Operations: Zealand Pharma A/S has been in operation since 1998, indicating a degree of stability.
- Marketed Products: The company has marketed products like Adlyxin and Lyxumia, suggesting a functional business model.
- Strategic Collaborations: Collaborations with reputable pharmaceutical companies provide some validation of its technology and expertise.
- Clinical Trials: The company is conducting Phase III clinical trials, demonstrating a commitment to drug development.
- Employee Count: The company employs 385 people, suggesting a sizable operation.
Common Questions About ZLDPF
What does Zealand Pharma A/S do?
Zealand Pharma A/S is a biotechnology company specializing in the discovery, development, and commercialization of peptide-based medicines. The company focuses on addressing unmet medical needs in gastrointestinal and metabolic diseases, as well as other specialty areas. Its portfolio includes marketed products like Adlyxin and Lyxumia for diabetes and Dasiglucagon for severe hypoglycemia, and a pipeline of drugs in clinical development, including treatments for congenital hyperinsulinism and short bowel syndrome. Zealand Pharma operates through strategic collaborations with major pharmaceutical companies.
What do analysts say about ZLDPF stock?
Analyst coverage of Zealand Pharma A/S (ZLDPF) is pending. Key valuation metrics to consider include the company's market capitalization of $2.89 billion, P/E ratio of 2.93, and profit margin of 70.0%. Growth considerations include the potential success of its Phase III clinical trials for Dasiglucagon and glepaglutide, as well as its strategic collaborations. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
What are the main risks for ZLDPF?
The main risks for Zealand Pharma A/S include the potential failure of its Phase III clinical trials for Dasiglucagon and glepaglutide, which could significantly impact its pipeline and future revenue. Regulatory delays or rejections for new drug approvals also pose a risk. Competition from other pharmaceutical companies and the potential for patent expirations on key products could erode its market share. Additionally, product liability claims and adverse events related to its drugs could negatively affect its financial performance and reputation.
How does Zealand Pharma A/S manage patent expiration risks?
Zealand Pharma A/S manages patent expiration risks through a combination of strategies, including actively pursuing new patent applications for novel formulations, delivery methods, and therapeutic uses of its existing drugs. The company also invests in research and development to create new peptide-based medicines with patentable features. Furthermore, Zealand Pharma strategically engages in lifecycle management activities to extend the market exclusivity of its products and mitigate the impact of biosimilar competition.
What are the key growth opportunities for ZLDPF in healthcare?
Zealand Pharma A/S's key growth opportunities in healthcare lie in the expansion of its existing product lines and the successful development and commercialization of its pipeline drugs. Specifically, the company aims to capitalize on the growing market for diabetes and gastrointestinal disorder treatments. The successful completion of Phase III clinical trials for Dasiglucagon and glepaglutide could lead to significant revenue growth. Additionally, expanding into new geographic markets and therapeutic areas represents further growth potential.
What are the key factors to evaluate for ZLDPF?
Zealand Pharma A/S (ZLDPF) currently holds an AI score of 68/100, indicating moderate score. Key strength: Strong expertise in peptide-based drug development.. Primary risk to monitor: Potential: Clinical trial failures for Dasiglucagon and glepaglutide.. This is not financial advice.
How frequently does ZLDPF data refresh on this page?
ZLDPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ZLDPF's recent stock price performance?
Recent price movement in Zealand Pharma A/S (ZLDPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong expertise in peptide-based drug development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-15.
- OTC market data may be limited or less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.